Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and...

Full description

Bibliographic Details

Main Authors:	Hübner, Hanna (Author) , Kurbacher, Christian M. (Author) , Kuesters, Geoffrey (Author) , Hartkopf, Andreas D. (Author) , Lux, Michael P. (Author) , Huober, Jens (Author) , Volz, Bernhard (Author) , Taran, Florin-Andrei (Author) , Overkamp, Friedrich (Author) , Tesch, Hans (Author) , Häberle, Lothar (Author) , Lüftner, Diana (Author) , Wallwiener, Markus (Author) , Müller, Volkmar (Author) , Beckmann, Matthias W. (Author) , Belleville, Erik (Author) , Ruebner, Matthias (Author) , Untch, Michael (Author) , Fasching, Peter Andreas (Author) , Janni, Wolfgang (Author) , Fehm, Tanja (Author) , Kolberg, Hans-Christian (Author) , Wallwiener, Diethelm (Author) , Brucker, Sara Y. (Author) , Schneeweiss, Andreas (Author) , Ettl, Johannes (Author)
Format:	Article (Journal)
Language:	English
Published:	11 November 2020
In:	BMC cancer Year: 2020, Volume: 20
ISSN:	1471-2407
DOI:	10.1186/s12885-020-07546-1
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07546-1
Author Notes:	Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss and Johannes Ettl